STL Index for: Eflornithine
Epidermal growth factor receptor (EGFR) inhibitors are part of an emerging class of anticancer medicines known as "targeted therapy". Adverse effects of such treatments are thought to be less severe, but can still be significant.
(Reprint from STL FP 7.2) Facial hair can be a distressing, chronic problem for many women. This article discusses assessment, treatment options, side-effects, and costs. Combination therapy and its benefits are also covered.
Twenty-two percent of women in North America have unwanted facial hair, which can cause embarrassment and result in a significant emotional burden. Eflornithine 13.9% cream can be used in combination with other treatments such as lasers and IPL to give the patient the best chance for successful hair removal.
Hirsutism can cause embarrassment and lead to anxiety and depression. There are a limited number of treatments available that vary in efficacy, degree of discomfort and cost. It is very important to make sure that the patient is aware of all the available treatment modalities, since no one method is effective for all patients or body locations, and results from therapy may not always be satisfactory.
Eflornithine HCl 13.9% cream (Vaniqa) is the first topical prescription treatment to be approved for the reduction of unwanted facial hair in women. It irreversibly inhibits ornithine decarboxylase, an enzyme that catalyzes the ratelimiting step for follicular polyamine synthesis, which is necessary for hair growth.